Myriad Genetics 获得了分子残留疾病 (MRD) 检测的关键专利，并提前确定了优先权日期。 Myriad Genetics secures a key patent for Molecular Residual Disease (MRD) testing with early priority date.
Myriad Genetics 获得了分子残留疾病 (MRD) 的基础专利，并提前确定了优先权日期。 Myriad Genetics secures a foundational patent for Molecular Residual Disease (MRD) with an early priority date. 美国专利商标局颁发了美国专利 11,932,910，名称为“组合 DNA 筛选”，涵盖了 Myriad 制备游离 DNA 的专有方法。 The US Patent and Trademark Office issued U.S. patent 11,932,910, titled "Combinatorial DNA Screening," covering Myriad's proprietary method of preparing cell-free DNA. 该方法增强了该公司提供肿瘤信息、高清 MRD 检测的能力，通过高灵敏度和特异性的测序来检测循环肿瘤 DNA (ctDNA)。 This method strengthens the company's ability to deliver tumor-informed, high-definition MRD assays, detecting circulating tumor DNA (ctDNA) through sequencing with high sensitivity and specificity.